Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Daratumumab, ixazomib, lenalidomide +/- dex for NDMM shows ORR of 96%, including a ≥CR rate of 32% and nearly 1/3 attained MRDneg; most common toxicities were fatigue, neutropenia, lymphopenia, neuropathy, diarrhea, nausea.”
Title: Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma
Authors: Shaji Kumar, Betsy Knopf, Erik Asmus, Eli Muchtar, Francis K. Buadi, Wilson Gonsalves, Melanie Thompson, David Dingli, Ronald Go, Rahma Warsame, Taxiarchis Kourelis, Lisa Hwa, Amie Fonder, Miriam Hobbs, Angela Dispenzieri, Suzanne Hayman, Nelson Leung, Moritz Binder, S. Vincent Rajkumar, Morie Gertz, Prashant Kapoor
You can read the Full Article on Blood Cancer Journal.
You can find other articles featuring Robert Orlowski on OncoDaily.
